Retrospective Review of Gynecologic Oncology Patients with Therapy-Induced Neutropenic Fever

McMeekin, D. Scott; Gazzaniga, Cristiana; Berman, Michael L.; DiSaia, Philip J.; Manetta, Alberto

doi:10.1006/gyno.1996.0223

Cited by 5 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…McMeekin et al . 14 reported that the source of fever was unexplained by examination or cultures in 56% of episodes in patients with gynecologic oncology. Shama et al .…”

Section: Discussionmentioning

confidence: 99%

“…In these reports, only patients receiving first-line chemotherapy were included, and no patients with recurrent disease were included 12 , 13 . To the best of our knowledge, the last comprehensive study of febrile neutropenia in patients with gynecologic malignancy was published in 1996 14 . There are insufficient data from patients who have received modern chemotherapy regimens to address these issues.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy

et al. 2015

View full text Add to dashboard Cite

Chemotherapy-induced neutropenia is a common complication in cancer treatment. In this study, we investigated chemotherapy-induced neutropenia that was recently detected in all patients with gynecologic malignancy. Between January 2009 and December 2011, we examined cases of chemotherapy-induced neutropenia reported in our hospital. We analyzed the incidence and clinical features of chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. During the study period, we administered over 1614 infusions (29 regimens) to 291 patients. The median age of the patients was 60 years (range 24–84 years). Chemotherapy-induced neutropenia occurred in 147 (50.5%) patients over 378 (23.4%) chemotherapy cycles. Febrile neutropenia occurred in 20 (6.9%) patients over 25 (1.5%) cycles. The mean duration of neutropenia and fever was 3.6 days (range 1–12 days) and 3.4 days (range 1–9 days), respectively. The source of fever was unexplained by examination or cultures in 14 (56.0%) cycles. There were two cases of neutropenia-related death. Chemotherapy-induced neutropenia was associated with older age (over 70 years) (P<0.0001), less than five previous chemotherapy cycles (P=0.02), disseminated disease (P=0.03), platinum-based regimens (P<0.0001), taxane-containing regimens (P<0.0001), and combined therapy (P<0.0001). Febrile neutropenia was associated with poor performance status (P<0.0001), no previous chemotherapy (P<0.05), disseminated disease (P<0.0001), and distant metastatic disease (P=0.03). Neither chemotherapy-induced neutropenia nor febrile neutropenia was associated with bone marrow metastases or previous radiotherapy. By identifying risk factors for febrile neutropenia, such as performance status, no previous chemotherapy, disseminated disease, and distant metastatic disease, the safe management of chemotherapy-induced neutropenia may be possible in patients with gynecologic malignancy.

show abstract

“…McMeekin et al . 14 reported that the source of fever was unexplained by examination or cultures in 56% of episodes in patients with gynecologic oncology. Shama et al .…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…One report found that more than half of febrile gynecology patients had no identifiable source. 7 There are limited data on the utility of commonly used laboratory and imaging studies. Because an improved understanding of fever may help direct diagnostic testing, improve patient care, and reduce health care expenditures, we aimed to identify the etiologies of fevers and examine the utility of diagnostic testing for a cohort of patients admitted for fever to the gynecologic oncology service of a tertiary care medical center.…”

mentioning

confidence: 99%

Etiology and Workup of Fevers in Gynecologic Oncology Patients

McCartney¹,

Sabo

Massad

et al. 2014

Int J Gynecol Cancer

View full text Add to dashboard Cite

The initial evaluation of the febrile gynecologic oncology patient without obvious source by history and examination should include urinalysis with reflex culture and blood cultures. Abdominopelvic and chest CT may be useful when fever persists and initial assessment is unrevealing. Chest x-ray is commonly done but infrequently diagnostic. Wound exploration may be important in patients with fevers for more than 30 days after surgery.

show abstract

Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer

Sharma

Rezai

Driscoll

et al. 2006

Gynecologic Oncology

View full text Add to dashboard Cite

Retrospective Review of Gynecologic Oncology Patients with Therapy-Induced Neutropenic Fever

Cited by 5 publications

References 1 publication

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy

Etiology and Workup of Fevers in Gynecologic Oncology Patients

Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer

Contact Info

Product

Resources

About